Aquinox Pharmaceuticals Inc. (AQXP) Has Plunged To A New Low After Study Failed
Markets2018-06-27
13 Views
Aquinox Pharmaceuticals Inc. (AQXP) announced Wednesday morning that its Phase 3 clinical trial of once-daily, oral rosiptor, for the treatment of interstitial cystitis/bladder pain syndrome, failed to meet its primary endpoint.
Source: RTTNews
The news, reports, views and opinions of authors (or source) expressed are their own and do not necessarily represent the views of CRWE World.
Berkshire Hathaway Inc. (NYSE: BRK.A) (NYSE: BRK.B) Reports Fourth Quarter and Full Year 2020
